보충 그림 2: RAS/RAF 동시변이 및 ERBB2 복제 수가 대장암에서 HER2 이질성과 HER2 표적 치료 반응성에 미치는 영향

Singh 등(월요일)이 이 문제를 연구하였다.

www.synapsesocial.com/papers/68e6f2a2b6db64358766d0e9 — DOI: https://doi.org/10.1158/1078-0432.25603663.v1

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Supplementary Figure 2 from <i>RAS/RAF</i> Comutation and <i>ERBB2</i> Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer· 2024
2. Supplementary Figure 4 from <i>RAS/RAF</i> Comutation and <i>ERBB2</i> Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer· 2024
3. Supplementary Figure 4 from <i>RAS/RAF</i> Comutation and <i>ERBB2</i> Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer· 2024
4. Supplementary Figure 1 from <i>RAS/RAF</i> Comutation and <i>ERBB2</i> Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer· 2024
5. Supplementary Figure 1 from <i>RAS/RAF</i> Comutation and <i>ERBB2</i> Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer· 2024